Table 2.
Prescription at baseline and follow‐up
| DPP4i Group (n = 1034) | BG group (n = 365) | |
|---|---|---|
| Baseline | ||
| Type of DPP4i | N/A | |
| Sitagliptin | 556 (53.8) | |
| 100 mg | 6 | |
| 50 mg | 496 | |
| ≤25 mg | 54 | |
| Alogliptin | 216 (20.9) | |
| 25 mg | 188 | |
| ≤12.5 mg | 28 | |
| Vildagliptin | 142 (13.7) | |
| 100 mg | 70 | |
| 50 mg | 72 | |
| Other type of DPP4i | 120 (11.6) | |
| Dose of metformin | N/A | |
| ≥2000 mg | 0 (0.0) | |
| ≥1000 mg, <2000 mg | 34 (9.3) | |
| <1000 mg | 329 (90.1) | |
| Buformin | 2 (0.6) | |
| Follow‐up | ||
| None of DM drug | 181 (17.5) | 61 (16.7) |
| Only OAD | ||
| Number of type of OAD | ||
| 1 | 525 (50.8) | 159 (43.6) |
| 2 | 237 (22.9) | 106 (29.0) |
| 3‐ | 83 (8.0) | 32 (8.8) |
| Insulin (or Insulin combined with OAD) | 5 (0.5) | 3 (0.8) |
| GLP‐1 analog (or GLP‐1 combined with OAD) | 3 (0.3) | 4 (1.1) |
| Patients continuing first kinds of OAD | 810 (78.3) | 269 (73.7) |
Note. N (%). There are no patients who received both insulin and GLP‐1 analog at the follow‐up prescription.
Abbreviations: BG, biguanide; DM, diabetes mellitus; DPP4i, dipeptidyl peptidase‐4 inhibitors; OAD, oral antidiabetic drug.